DUESSELDORF, Germany--(BUSINESS WIRE)--miacom diagnostics specializes on the development and production of medical tests for the detection of acute infectious diseases. The company with headquarters in Duesseldorf, Germany, was founded in 2006 based on the vision of developing faster and better diagnostic methods than currently available to the healthcare system. New diagnostic tests, delivering precise information on an infection’s causative agent faster and with higher precision, can reduce the morbidity and mortality for many patients. In addition to its existing sepsis kits miacom, diagnostics is now presenting a further CE-marked product based on the same proprietary technology. It is targeted at the rapid detection of clinically most relevant pneumonia causing pathogens. The lucesco pneumonia I test simultaneously detects the twelve most important gram-negative bacteria. In as little as 40 minutes a physician may know what he and the patient are fighting against – one to two days earlier than current tests allow. The fast test results significantly increase the chances for a targeted and successful treatment. Detection is performed directly on respiratory secretions, eliminating the hitherto required tedious culturing of pathogens.
